Gary Rojewski has 29-years experience in the pharmaceutical industry. During that time he has worked for Procter & Gamble Pharmaceuticals, Warner Chilcott Pharmaceuticals and most recently Actavis. Throughout his pharmaceutical career he has been responsible for commercializing pharmaceutical products.
CEO – Gary Rojewski
LATEST ENZYME BIOSYSTEMS PRESS RELEASE & NEWS
The management team of Enzymebiosystems (ENZB) announced they have moved further along the process of evaluating an enzyme compound which they believe has specific therapeutic value in fighting tumors. In an effort to evaluate this compound, management has had a series of meetings with various contract research organizations to enlist their expertise in performing animal studies. The research will study the use of a antitumor natural product called amooranin. Specifically, the two areas of this study will include: 1) an exam of the vitro cytotoxicity of amooranin against hepatocellular carcinoma cells, and 2) investigate the dose responsive antitumor actions of amooranin against chemically induced hepatic tumorgenesis in rats and dogs.
Management hopes the research will identify an enzyme compound that will lead to an Investigational New Drug application (IND) with the U.S. Federal Drug Association (FDA). It is still too early to determine if this project has any potential value for the company, and there are no assurances that the company will ever obtain an IND for this compound.